Novo Nordisk says strong early demand for its newly launched Wegovy weight-loss pill is improving its outlook. Multiple outlets report that the company raises its guidance for 2026 after results show declines are less severe than it previously expected. Bloomberg adds that the company’s earlier outlook anticipated a larger fall in profit and sales, but that the worst declines are now expected to be 12% for both profit and sales, rather than 13%. CNBC and the Financial Times likewise link the upgrade to performance driven by the pill, including strong sales in the first quarter. MarketWatch reports that Novo Nordisk describes the pill’s adoption as the fastest take-up in the weight-loss drug category’s history. Across coverage, the common theme is that while Novo still expects overall profit and sales to decline for the year, the new product is offsetting part of that downturn and is strengthening the company’s forward outlook. Shares respond positively to the updated forecast in reported trading.
Novo Nordisk lifts forecasts as Wegovy pill demand outpaces expectations
Novo Nordisk says strong early demand for its newly launched Wegovy weight-loss pill is improving its outlook. Multiple outlets report that the company raises its guidance for 2026 after results show...
- Novo Nordisk raises its financial guidance for 2026 after strong performance from the newly launched Wegovy pill.
- The company attributes improved results to demand for the Wegovy pill, including strong first-quarter sales.
- Novo Nordisk expects the worst drop in profit and sales to be 12%, compared with 13% in an earlier forecast.
- Novo Nordisk says the Wegovy pill’s take-up is the fastest in the weight-loss drug history, according to MarketWatch.
- Reported coverage indicates investors respond positively to the forecast increase, with shares rising.
Novo Nordisk on Wednesday narrowly improved its financial guidance for a year where it still sees profit and sales falling after the fastest take-up in weight-loss drug history for its Wegovy pill.
3 months agoShares in Danish drugmaker surge on positive signal from results
3 months agoNovo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.
3 months agoNovo Nordisk A/S said this year’s declines won’t be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg’s Sanne Wass reports from Copenhagen.
3 months ago
UAE official backs 49% stake in Trump family’s bank venture, WSJ reports
The Wall Street Journal reports that a senior UAE national security figure is taking a 49% stake in a bank venture backe...
American Airlines adds Vienna and six other international routes for 2027
American Airlines announces plans to launch seven new international routes in 2027, including flights to Vienna. The car...
US nears deal for long-term access to Venezuela’s oil reserves, sources say
The United States is reportedly close to reaching an agreement to secure long-term access to Venezuela’s oil reserves, w...